Chen Y, et al. - Given the potential of donor-derived CD19-directed chimeric antigen receptor-modified (CAR) T cells in curing leukaemia, authors aimed at confirming their effectiveness and safety in relapsed B-cell acute lymphoblastic leukaemia (B-ALL) cases after haploidentical haematopoietic stem cell transplantation (haplo-HSCT). As per findings, donor-derived CAR T-cell infusion seemed to be effective and safe for relapsed B-ALL after haplo-HSCT. However, larger clinical studies seemed required to confirm the results.